[Pathological findings as determinant factors of prognosis of renal cell carcinoma].
Clinicopathological studies were made on 105 patients with renal cell carcinoma who visited us from January 1978 to August 1989. The results were as follows: 1. Overall 3, 5 and 10-year survival rates were 60.4%, 49.8% and 44.5%, respectively. 2. Patients in Robson stage I survived longer than those in stage III, and patients in stage II survived longer than those in stage IV with a significant difference. 3. A significant difference did not exist between patients in stages lower than pT2 and those in pT3a, while patients in pT3a survived longer than those in stages higher than pT3b. 4. Patients with grade 1 tumors survived longer than those with grade 2 tumors, and patients with grade 2 tumors survived longer than those with grade 3 tumors with a significant difference. 5. Patients with clear cell subtype survived longer than those with granular cell subtype and mixed subtype with a significant difference, while a significant difference did not exist between patients with granular cell subtype and those with mixed subtype. 6. Patients with INF alpha tumors survived longer than those with INF beta tumors with a significant difference. There was the same significant difference in patients with grade 2 tumors.
Sato
K
K
Department of Urology, University of Tsukuba, School of Medicine.
Kawai
K
K
Iwasaki
A
A
Ishikawa
H
H
Koiso
K
K
Kamma
H
H
Ogata
T
T
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002292:Carcinoma, Renal Cell / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D011379:Prognosis; D015996:Survival Rate
D007370:Interferon Type I